News
Press ReleaseRevive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Revive Therapeutics explores Bucillamine as a cancer therapy with a top U.S. cancer institute, backed by NIH/government funding. Results expected soon.
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
Revive Therapeutics Announces Results of Annual Shareholder Meeting
Revive Therapeutics is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
Revive Therapeutics shares an update on R&D efforts, focusing on Bucillamine for infectious diseases and medical countermeasures. Learn more about their progress.
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Revive Therapeutics shares an update on R&D efforts, focusing on Bucillamine for infectious diseases and medical countermeasures. Learn more about their progress.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics updates on its research evaluating Bucillamine for nerve agent exposure, showcasing advancements in innovative therapeutic solutions